Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $1,340 | 2 | 93.5% |
| Education | $57.62 | 3 | 4.0% |
| Food and Beverage | $36.08 | 2 | 2.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eisai Inc. | $1,354 | 3 | $0 (2024) |
| Merck Sharp & Dohme LLC | $39.62 | 2 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $22.18 | 1 | $0 (2019) |
| PFIZER INC. | $18.00 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $688.00 | 2 | Eisai Inc. ($670.00) |
| 2023 | $723.52 | 4 | Eisai Inc. ($683.90) |
| 2019 | $22.18 | 1 | Novartis Pharmaceuticals Corporation ($22.18) |
All Payment Transactions
7 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/22/2024 | PFIZER INC. | INLYTA (Drug) | Education | In-kind items and services | $18.00 | General |
| Category: ONCOLOGY | ||||||
| 01/17/2024 | Eisai Inc. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $670.00 | General |
| Category: Oncology | ||||||
| 12/15/2023 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $13.90 | General |
| Category: Oncology | ||||||
| 12/05/2023 | Eisai Inc. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $670.00 | General |
| Category: Oncology | ||||||
| 03/02/2023 | Merck Sharp & Dohme LLC | WELIREG (Drug) | Education | In-kind items and services | $19.81 | General |
| Category: ONCOLOGY | ||||||
| 02/08/2023 | Merck Sharp & Dohme LLC | WELIREG (Drug) | Education | In-kind items and services | $19.81 | General |
| Category: ONCOLOGY | ||||||
| 07/19/2019 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug), TAFINLAR | Food and Beverage | In-kind items and services | $22.18 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 146 | 250 | $87,555 | $26,672 |
| 2022 | 6 | 193 | 350 | $96,740 | $32,321 |
| 2021 | 7 | 192 | 366 | $99,378 | $34,956 |
| 2020 | 3 | 81 | 166 | $61,723 | $14,721 |
All Medicare Procedures & Services
19 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 54 | 123 | $46,900 | $14,659 | 31.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 61 | 96 | $25,160 | $7,624 | 30.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 31 | 31 | $15,495 | $4,389 | 28.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 51 | 80 | $24,746 | $9,452 | 38.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 26 | 94 | $27,328 | $8,189 | 30.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 46 | 80 | $17,422 | $6,105 | 35.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 34 | 34 | $15,927 | $5,053 | 31.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 21 | 41 | $8,323 | $2,483 | 29.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 15 | 21 | $2,993 | $1,039 | 34.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 41 | 93 | $28,123 | $11,487 | 40.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 42 | 71 | $15,201 | $5,641 | 37.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 21 | 63 | $17,837 | $5,590 | 31.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 33 | 33 | $15,144 | $5,037 | 33.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 24 | 75 | $14,783 | $4,630 | 31.3% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 14 | 14 | $4,920 | $1,505 | 30.6% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 17 | 17 | $3,371 | $1,065 | 31.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 19 | 59 | $22,572 | $5,550 | 24.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 33 | 78 | $22,189 | $5,257 | 23.7% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 29 | 29 | $16,962 | $3,914 | 23.1% |
About Evan Hall
Evan Hall is a Medical Oncology healthcare provider based in Seattle, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/03/2012. The National Provider Identifier (NPI) number assigned to this provider is 1306102413.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Evan Hall has received a total of $1,434 in payments from pharmaceutical and medical device companies, with $688.00 received in 2024. These payments were reported across 7 transactions from 4 companies. The most common payment nature is "Consulting Fee" ($1,340).
As a Medicare-enrolled provider, Hall has provided services to 612 Medicare beneficiaries, totaling 1,132 services with total Medicare billing of $108,670. Data is available for 4 years (2020–2023), covering 19 distinct procedure/service records.
Practice Information
- Specialty Medical Oncology
- Location Seattle, WA
- Active Since 04/03/2012
- Last Updated 07/30/2019
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1306102413
Products in Payments
- Lenvima (Drug) $1,354
- WELIREG (Drug) $39.62
- MEKINIST (Drug) $22.18
- INLYTA (Drug) $18.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Seattle
Bart Scott
Medical Oncology — Payments: $1.5M
Petros Grivas, M.d, M.D
Medical Oncology — Payments: $683,103
Evan Yu
Medical Oncology — Payments: $356,321
Gary Lyman, Md, MD
Medical Oncology — Payments: $176,021
Jerald Radich, Md, MD
Medical Oncology — Payments: $171,817
David Maloney
Medical Oncology — Payments: $167,323